A Randomized, Double-Blind, Phase II Trial of Fulvestrant Plus Enzastaurin Versus Fulvestrant Plus Placebo in Aromatase Inhibitor-Resistant Metastatic Breast Cancer.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 31 Aug 2017
At a glance
- Drugs Enzastaurin (Primary) ; Fulvestrant
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 25 Aug 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 06 Dec 2016 This study has been completed in Germany.
- 30 Nov 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History